Experimental Treatment for Type 1 Diabetes Patients Shows Promise
During the 18 month study, physicians used Continuous Glucose Monitoring Systems to monitor the effects of the islet cell transplant procedure on patients with type 1 diabetes. The results were intriguing.
"Our findings suggest that the majority of patients with Type 1 diabetes who have received an islet transplant benefit from near normal metabolic control, with fewer and shorter episodes of hypoglycemia," said Lisa Gorn, DO, the study's primary author. "These patients also spent longer periods of time in normoglycemia overall.
At the 2008 AACE Annual Meeting diabetes will be taking center stage. A special symposium titled "Clinical Trials Targeting Glycemia: What Do We Expect to Learn?" will consider the impact of glucose control through studies including ACCORD, ADVANCE, VADT, and others. Related sessions of interest include "Insulin Resistance and Atherosclerosis: The Missing Link," and "Hypoglycemia: The Limiting Factor in the Glycemic Management of Diabetes."
Media Registration: http://www.aace.com/meetings/ams/2008/MRGuidelines.php
About AACE: http://www.aace.com/org/history.php
About the AACE Annual Meeting: http://www.aace.com/meetings/ams/2008/
Other AACE Annual Meeting News:
http://www.aace.com/newsroom/press/2008/index.php?r=20080112
http://www.aace.com/newsroom/press/2008/index.php?r=20080111
http://www.aace.com/newsroom/press/2008/index.php?r=20080110
http://www.aace.com/newsroom/press/2008/index.php?r=20080109
http://www.aace.com/newsroom/press/2008/index.php?r=20080108
http://www.aace.com/newsroom/press/2008/index.php?r=20080107
Contact
AACE, Orlando
Bryan Campbell or Greg Willis, 904-353-7878
bcampbell@aace.com
gwillis@aace.com
Posted: April 2008
